Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges-Reference-Cited by-同舟云学术

Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges

Published:2022-03-25 Issue:6 Volume:40 Page:577-586
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Gomes Manuel^ORCID,Latimer Nick,Soares Marta,Dias Sofia,Baio Gianluca,Freemantle Nick,Dawoud Dalia,Wailoo Allan,Grieve Richard

Funder

Yorkshire Cancer Research

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-022-01141-x.pdf

Reference57 articles.

1. Bullement A, Podkonjak T, Robinson MJ, Benson E, Selby R, Hatswell AJ, et al. Real-world evidence use in assessments of cancer drugs by NICE. Int J Technol Assess Health Care. 2020:1–7.

2. Goring S, Taylor A, Muller K, Li TJJ, Korol EE, Levy AR, et al. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review. BMJ Open. 2019;9(2):e024895.

3. Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open. 2016;6(6):e011666.

4. Griffiths EA, Macaulay R, Vadlamudi NK, Uddin J, Samuels ER. The role of noncomparative evidence in health technology assessment decisions. Value Health. 2017;20(10):1245–51.

5. Chan K, Nam S, Evans B, de Oliveira C, Chambers A, Gavura S, et al. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 2020;10(1):e032884.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy;Current Medical Research and Opinion;2024-07

2. Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps;Value in Health;2024-05

3. Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments;PharmacoEconomics;2024-04-01

4. Identification of required capabilities of digital health ecosystems when preventing and managing non-communicable diseases;DIGITAL HEALTH;2024-01

5. Target trial emulation: Do antimicrobials or gastrointestinal nutraceuticals prescribed at first presentation for acute diarrhoea cause a better clinical outcome in dogs under primary veterinary care in the UK?;PLOS ONE;2023-10-04